| Literature DB >> 35975359 |
Wending Huang1,2, Lun Xu1,2, Weiluo Cai1,2, Mo Cheng1,2, Zhengwang Sun1,2, Shengping Wang2,3, Wangjun Yan1,2.
Abstract
OBJECTIVE: S2-alar-iliac (S2AI) screw technique is widely used in spinal surgery, but it is rarely seen in the field of spinal tumors. The aim of the study is to report the preliminary outcomes of the freehand S2AI screw fixation after lumbosaral tumor resection.Entities:
Keywords: S2-alar-iliac screw; freehand; lumbosacral fixation; lumbosacral spine; tumor
Mesh:
Year: 2022 PMID: 35975359 PMCID: PMC9483049 DOI: 10.1111/os.13434
Source DB: PubMed Journal: Orthop Surg ISSN: 1757-7853 Impact factor: 2.279
Fig. 1(A) Entry point (EP) of S2AI screw is 2 mm lateral to the midpoint between the S1 and S2 dorsal foramen. The trajectory direction was 20°–30° caudally in the sagittal plane (B) and approximately 40° horizontally in the axial plane (C), pointing to the anterior inferior iliac spine (AIIS). (D) Anteroposterior diagram of the postoperative reconstruction of lumbo‐pelvis with S2AI screws after tumor resection. (E) Lateral diagram showed the sagittal effect after lumbopelvic reconstruction
Summary data of 23 patients with at least 12‐month follow‐up after S2AI screw placement
| No. | Sex | Age | Location | Diagnosis | Revision surgery | ATBS | WBB staging | Surgical strategy | PE |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 73 | L5 | Lung cancer | No | Target | 4–8, A–C | Gross total resection | No |
| 2 | F | 47 | S1 | Breast cancer | No | CT + ET + diphosphonate | 5–8, B–D | Separation surgery | No |
| 3 | M | 64 | L5 | Renal carcinoma | No | Target+ diphosphonate | 5–8, B–D | Gross total resection | Yes |
| 4 | F | 41 | L5‐S1 | Breast cancer | No | CT + ET + diphosphonate | 4–6, A–C | Separation surgery | No |
| 5 | F | 52 | L5 | Breast cancer | No | CT + ET + RT + diphosphonate | 5–8, A–C | Gross total resection | No |
| 6 | F | 50 | S1 | Lung cancer | No | Target | 6–10, A–D | Piecemeal resection | No |
| 7 | M | 54 | L5 | Lung cancer | No | CT + diphosphonate | 5–8, B–D | Gross total resection | No |
| 8 | M | 59 | S1 | Hepatocarcinoma | No | Target | 4–7, A–D | Piecemeal resection | Yes |
| 9 | F | 58 | S1 | Rectal cancer | No | CT + Target + RT + diphosphonate | 4–8, A–D | Piecemeal resection | No |
| 10 | F | 60 | L5‐S1 | Breast cancer | No | CT + ET + diphosphonate | 5–10, B–D | Piecemeal resection | No |
| 11 | F | 38 | L5 | Cervical cancer | No | CT + diphosphonate | 6–9, A–C | Piecemeal resection | No |
| 12 | M | 53 | S1 | Renal carcinoma | No | No | 3–5, B–C | Piecemeal resection | No |
| 13 | M | 54 | S1 | Hepatocarcinoma | No | No | 7–10, A–D | Piecemeal resection | Yes |
| 14 | F | 30 | L5 | GCTB | Yes | Denosumab | 5–8, A–D | Gross total resection | Yes |
| 15 | F | 30 | L5 | GCTB | No | Denosumab | 6–9, A–D | En bloc resection | Yes |
| 16 | F | 51 | S1 | Chondrosarcoma | No | No | 4–5, B–C | En bloc resection | No |
| 17 | M | 22 | L4–5 | Synovial sarcoma | No | CT | 3–8, A–D | Gross total resection | Yes |
| 18 | M | 30 | S1 | Chordoma | No | No | 5–8, B–D | En bloc resection | No |
| 19 | M | 64 | L5‐S1 | Schwannoma | No | No | 4–6, A–D | En bloc resection | No |
| 20 | M | 33 | S1 | Paraganglioma | No | No | 5–8, A–D | Gross total resection | No |
| 21 | F | 55 | L5 | LCH | No | No | 4–8, B–D | En bloc resection | No |
| 22 | M | 15 | L4–5 | Ewing sarcoma | Yes | CT | 4–7, A–D | Gross total resection | Yes |
| 23 | M | 55 | L5‐S1 | SFT | No | No | 5–9, A–D | Gross total resection | Yes |
Abbreviations: ATBS, Adjuvant therapy before surgery; CT, chemotherapy; ET, Endocrine therapy; LCH, Langerhans cell histiocytosis; PE, preoperative embolization;GCTB, giant cell tumor of bone; RT, radiotherapy; SFT, solitary fibrous tumor.
Surgical data and outcomes of patients with at least 12‐month follow‐up after S2AI screw placement
| No. | OT (mins) | BL (ml) | SL (mm) | SD (mm) | Screw Breach | Reconstruction | Complications | Adjuvant therapy | FU/outcomes |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 210 | 1400 | 80 | 7.0 | No | L3–4, S1 PS + S2AI + AVB + BC | Target+ diphosphonate | 31/DOD | |
| 2 | 170 | 800 | 80 | 7.0 | No | L4–5 PS + S2AI | ET + diphosphonate | 34/SWT | |
| 3 | 260 | 1500 | 80 | 7.0 | No | L3–4, S1 PS + S2AI + AVB + AB | Cerebrospinal fluid leak | Target+ diphosphonate | 60/TFS |
| 4 | 190 | 800 | 80 | 7.5 | No | L3–5 PS + S2AI | ET + diphosphonate | 29/SWT | |
| 5 | 250 | 1800 | 80 | 7.0 | Right (grade 1) | L3–4, S1 PS + S2AI+ TM + BC | ET + diphosphonate | 56/SWT | |
| 6 | 175 | 1300 | 80 | 7.0 | No | L4–5 PS + S2AI | Screw lucent zone | Target+ diphosphonate | 36/SWT |
| 7 | 265 | 1400 | 90 | 8.5 | No | L3–4, S1 PS + S2AI + AVB + BC | CT + RT+ diphosphonate | 14/DOD | |
| 8 | 155 | 1900 | 90 | 8.5 | No | L4–5 PS + S2AI | Target+RT+ diphosphonate | 21/SWT | |
| 9 | 190 | 600 | 80 | 7.0 | No | L4–5 PS + S2AI | Wound infection | Target+ diphosphonate | 13/DOD |
| 10 | 210 | 1000 | 80 | 7.0 | No | L3–4, S1 PS + S2AI + AVB + BC | ET + RT + diphosphonate | 20/SWT | |
| 11 | 195 | 1100 | 80 | 8.5 | No | L3–4, S1 PS + S2AI + AVB + BC | RT + diphosphonate | 19/SWT | |
| 12 | 180 | 4000 | 80 | 8.5 | No | L4–5 PS + S2AI | Target+PD1 + diphosphonate | 15/SWT | |
| 13 | 170 | 1500 | 90 | 8.5 | No | L4–5 PS + S2AI | Cerebrospinal fluid leak | Target+diphosphonate | 15/SWT |
| 14 | 290 | 3200 | 80 | 7.0 | Right (grade 2) | L3–4, S1 PS + S2AI + AVB + AB | Denosumab | 52/TFS | |
| 15 | 275 | 1600 | 80 | 7.0 | No | L2–4, S1 PS + S2AI + AVB + AB | Denosumab | 24/TFS | |
| 16 | 205 | 700 | 80 | 7.0 | Left (grade 1) | L4–5 PS + S2AI | No | 26/TFS | |
| 17 | 370 | 2200 | 80 | 7.0 | No | L3–4, S1 PS + S2AI + AVB + AB | CT + RT | 32/TFS | |
| 18 | 210 | 900 | 90 | 8.5 | No | L4–5 PS + S2AI | RT | 44/TFS | |
| 19 | 190 | 1200 | 80 | 7.5 | No | L4–5 PS + S2AI | Delayed wound infection | No | 27/TFS |
| 20 | 160 | 600 | 80 | 7.5 | No | L4–5 PS + S2AI | RT | 26/SWT | |
| 21 | 270 | 1200 | 80 | 7.0 | No | L3–4, S1 PS + S2AI + AVB + AB | Cerebrospinal fluid leak | No | 56/TFS |
| 22 | 310 | 1700 | 80 | 7.0 | No | L2–3, S1 PS + S2AI + AVB + AB | Screw lucent zone | CT + RT | 60/SWT |
| 23 | 265 | 3500 | 80 | 7.5 | No | L3–4, S1 PS + S2AI + TM + BC | Lung infection | Target (Pazopanib) + RT | 16/DOD |
Abbreviations: AB, autogenous/allogeneic bone; AVB, artificial vertebral body; BC, bone cement; CT, chemotherapy; DOD, died of disease; ET, Endocrine therapy; FU, Follow‐up; OT, operation time; PD1: programmed cell death protein‐1 inhibitor; PS, pedicle screws; RT, radiotherapy; SD, screw diameter; SL, Screw length; SWT, survival with tumor; TFS, tumor free survival; TM, titanium mesh.
Fig. 2Case 15. Giant cell tumor of bone at L5 in a 30‐year‐old woman. (A) Sagittal T2‐weighted magnetic resonance imaging showed the tumor involving L5 vertebral body. Coronal (B) and axial (C) T1‐weighted enhanced magnetic resonance imaging demonstrated the extent of the tumor with spinal canal compromise. (D) Axial computed tomographic scan demonstrated the tumor with osteolytic destruction. Anteroposterior (E) and lateral (F) radiographs showed a stable construct at 2 years postoperatively. (G) Postoperative computed tomographic scan demonstrated no breach of the screws
Fig. 3Postoperative computed tomographic scan on axial slice showed an anterior breach of S2AI screw on the right side
Fig. 4Kaplan–Meier survival curve